|
Investigation of the efficacy of imidazolyl ethanamide pentandioic acid (IEPA) to reduce chemotherapy-induced myelosuppression (CIM) in breast cancer patients. |
|
|
|
Consulting or Advisory Role - Lilly; Myelo Therapeutics GmbH |
Travel, Accommodations, Expenses - Medac |
|
|
Employment - Myelo Therapeutics GmbH |
Leadership - Myelo Therapeutics GmbH; Treamid Therapeutics |
Stock and Other Ownership Interests - Myelo Therapeutics GmbH; Treamid Therapeutics |
Consulting or Advisory Role - Bayer; CCEry |
Patents, Royalties, Other Intellectual Property - Myelo Therapeutics GmbH; Treamid Therapeutics |
|
|
Honoraria - AstraZeneca; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AMGEN; AstraZeneca; Myelo Therapeutics GmbH; Novartis; Pantarhei Bioscience; Pfizer; Roche |
Research Funding - AstraZeneca (Inst); BioNTech (Inst); Myelo Therapeutics GmbH (Inst); Pantarhei Bioscience (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
Honoraria - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Hexal; Merck Sharp & Dohme; Myelo Therapeutics GmbH; Novartis; Pfizer; Puma Biotechnology; Roche; Teva |
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Hexal; Merck Sharp & Dohme; Myelo Therapeutics GmbH; Novartis; Pfizer; Puma Biotechnology; Roche; Teva |
Research Funding - BioNTech (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Genomic Health; Genomic Health; Novartis; Roche; Tesaro |
Research Funding - Genomic Health (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Employment - Myelo Therapeutics GmbH |
|
|
Employment - Myelo Therapeutics GmbH |
|
|
No Relationships to Disclose |